MedTrace Logo

Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. (ENDOBIO)

NCT05339451 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 345

Last updated 2025-02-24

No results posted yet for this study

Summary

Endometriosis is a chronic, benign, estrogen-dependent disease characterized by endometrial tissue that is implanted outside the uterus into the ovaries, intestines, or peritoneum but also outside the pelvis. It is a common disease that affects 7-10% of women around the world. The most common symptoms are pain and infertility. The diagnosis is histological after removal of lesions with laparoscopy (sensitivity 94%, specificity 79%), and treatment is symptomatic.

At present, there is not a laboratory test that allows early and adequate diagnosis of endometriosis and therefore it can take up to 10 years for a patient to be diagnosed and patients often suffer from the disease.

The purpose of our study is to investigate biomarkers associated with endometriosis and prove their use in the diagnosis and staging of endometriosis. The biomarkers will be studied even in relationship to clinical manifestations of the disease, as markers of relapse and as fertility markers. Meanwhile, quality of life of patients with advanced stages of endometriosis postoperatively will be studied.

Conditions

  • Endometriosis

Interventions

DIAGNOSTIC_TEST

Blood biomarkers

Blood biomarkers in plasma and serum.

Sponsors & Collaborators

  • Karolinska Institutet

    collaborator OTHER

  • Södersjukhuset (Stockholm South General Hospital)

    collaborator UNKNOWN

  • Akademiska University Hospital, Uppsala, Sweden

    collaborator UNKNOWN

  • Region Stockholm

    lead OTHER_GOV

Principal Investigators

  • Kenny Rodriguez-Wallberg, Professor · Karolinska Institutet

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-04
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05339451 on ClinicalTrials.gov